Treatment of light chain deposition disease with bortezomib and dexamethasone.
作者信息
Kastritis Efstathios, Migkou Magdalini, Gavriatopoulou Maria, Zirogiannis Panos, Hadjikonstantinou Valsamakis, Dimopoulos Meletios A
出版信息
Haematologica. 2009 Feb;94(2):300-2. doi: 10.3324/haematol.13548. Epub 2008 Dec 9.
Abstract
摘要
相似文献
1
Treatment of light chain deposition disease with bortezomib and dexamethasone.硼替佐米与地塞米松治疗轻链沉积病
Haematologica. 2009 Feb;94(2):300-2. doi: 10.3324/haematol.13548. Epub 2008 Dec 9.
2
Bortezomib to treat the TEMPI syndrome.硼替佐米治疗TEMPI综合征。
N Engl J Med. 2012 May 10;366(19):1843-5. doi: 10.1056/NEJMc1202649.
3
[Bortezomib-based therapy in patients with light chain deposition disease].
Vnitr Lek. 2014 Oct;60(10):821-6.
4
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.来那度胺和地塞米松治疗沙利度胺或硼替佐米方案治疗后的系统性 AL 淀粉样变性。
Br J Haematol. 2014 Sep;166(6):842-8. doi: 10.1111/bjh.12973. Epub 2014 Jun 13.
5
Complete and partial responses of the TEMPI syndrome to bortezomib.硼替佐米对TEMPI综合征的完全缓解和部分缓解。
N Engl J Med. 2012 Aug 23;367(8):778-80. doi: 10.1056/NEJMc1205806.
6
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.移植术后供体肾来源的光链沉积病影响胃肠道。
Int J Hematol. 2012 Jul;96(1):125-31. doi: 10.1007/s12185-012-1090-1. Epub 2012 May 10.
7
Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.一名多发性骨髓瘤患者的硬化性黏液水肿和皮肤-神经综合征经地塞米松和硼替佐米有效治疗。
Am J Hematol. 2011 Oct;86(10):893-6. doi: 10.1002/ajh.22131.
8
Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.硼替佐米与地塞米松联合治疗对一名伴有多发溶骨性病变和髓外受累的浆细胞白血病患者的疗效。
Acta Oncol. 2007;46(2):262-4. doi: 10.1080/02841860600897975.
9
Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.硼替佐米与地塞米松作为初诊多神经病、器官肿大、内分泌病、M蛋白和皮肤改变综合征合并肾衰竭患者的一线治疗方案。
Leuk Lymphoma. 2012 Dec;53(12):2527-9. doi: 10.3109/10428194.2012.690515. Epub 2012 Jun 12.
10
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.治疗轻链淀粉样变性中的晚期心脏损害：仍存在未满足的需求。
Haematologica. 2014 Sep;99(9):1407-9. doi: 10.3324/haematol.2014.113464.
引用本文的文献
1
Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus.优化单克隆免疫球蛋白沉积病的肾脏反应评估：挑战、局限性及达成共识的必要性。
Leukemia. 2025 Aug 5. doi: 10.1038/s41375-025-02686-4.
2
Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature.达雷妥尤单抗治疗累及肾脏的轻链沉积病可预防肾功能进展：1例随访3年的病例报告及文献复习
Front Oncol. 2025 Jan 30;15:1466323. doi: 10.3389/fonc.2025.1466323. eCollection 2025.
3
Unraveling monoclonal gammopathy of renal significance: a mini review on kidney complications and clinical insights.解读具有肾脏意义的单克隆丙种球蛋白病：关于肾脏并发症及临床见解的小型综述
Front Nephrol. 2024 Sep 12;4:1439288. doi: 10.3389/fneph.2024.1439288. eCollection 2024.
4
Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies.轻链沉积病：发病机制、临床特征及治疗策略
Ann Hematol. 2025 Apr;104(4):2083-2093. doi: 10.1007/s00277-024-05911-9. Epub 2024 Aug 28.
5
Treatment and Outcome of Light Chain Deposition Disease in the Era of Novel Agents and Transplant.新型药物与移植时代轻链沉积病的治疗与结局
Indian J Hematol Blood Transfus. 2024 Jan;40(1):169-171. doi: 10.1007/s12288-023-01681-y. Epub 2023 Jul 21.
6
Dyspnea and cough in a 68-year-old female with light chain deposition disease.一名68岁患有轻链沉积病的女性出现呼吸困难和咳嗽。
Respir Med Case Rep. 2023 Mar 20;43:101839. doi: 10.1016/j.rmcr.2023.101839. eCollection 2023.
7
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.评估单克隆免疫球蛋白沉积病治疗后的肾脏结局：强调需要采用共识方法。
Am J Hematol. 2023 Mar;98(3):421-431. doi: 10.1002/ajh.26801. Epub 2023 Jan 1.
8
Treatment of Light Chain Deposition Disease: A Systematic Review.轻链沉积病的治疗：一项系统综述
J Hematol. 2022 Aug;11(4):123-130. doi: 10.14740/jh1038. Epub 2022 Aug 30.
9
Sjögren's syndrome as a cause of both lymphoid interstitial pneumonia and light chain deposition disease in a single patient.干燥综合征导致单个患者同时患有淋巴间质肺炎和轻链沉积病。
BMJ Case Rep. 2022 Jun 24;15(6):e249747. doi: 10.1136/bcr-2022-249747.
10
Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone.使用环磷酰胺、沙利度胺和地塞米松成功治疗轻链沉积病（LCDD）后的肾脏病理变化。
Ren Fail. 2021 Dec;43(1):1425-1427. doi: 10.1080/0886022X.2021.1988967.
本文引用的文献
1
Long-term outcome of autologous stem cell transplantation in light chain deposition disease.轻链沉积病自体干细胞移植的长期预后
Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.
2
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.硼替佐米与地塞米松联合治疗轻链（AL）淀粉样变性。
Haematologica. 2007 Oct;92(10):1351-8. doi: 10.3324/haematol.11325.
3
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.硼替佐米为主的化疗对多发性骨髓瘤患者急性肾衰竭的逆转作用
Haematologica. 2007 Oct;92(10):1411-4. doi: 10.3324/haematol.11463.
4
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Blood. 2007 Jul 1;110(1):345-53. doi: 10.1182/blood-2006-10-054502. Epub 2007 Mar 20.
5
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.硼替佐米对晚期肾衰竭多发性骨髓瘤患者的活性及安全性：一项多中心回顾性研究
Blood. 2007 Mar 15;109(6):2604-6. doi: 10.1182/blood-2006-09-046409. Epub 2006 Nov 30.
6
The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage.系膜作为肾小球病性轻链和重链的靶标：轻链和重链介导的肾小球损伤的发病机制探讨
Contrib Nephrol. 2007;153:116-34. doi: 10.1159/000096764.
7
Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.蛋白酶体阻断通过协同下调I型胶原蛋白和金属蛋白酶组织抑制剂-1，并上调人皮肤成纤维细胞中金属蛋白酶-1的产生，发挥抗纤维化活性。
FASEB J. 2006 Mar;20(3):562-4. doi: 10.1096/fj.05-4870fje. Epub 2006 Jan 12.
8
High dose chemotherapy in light chain or light and heavy chain deposition disease.高剂量化疗用于轻链或轻链与重链沉积病。
Kidney Int. 2004 Feb;65(2):642-8. doi: 10.1111/j.1523-1755.2004.00427.x.
9
Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.合并肾脏受累的轻链沉积病：临床特征及预后因素
Am J Kidney Dis. 2003 Dec;42(6):1154-63. doi: 10.1053/j.ajkd.2003.08.040.
10
NF-kappa B as a therapeutic target in multiple myeloma.核因子-κB作为多发性骨髓瘤的治疗靶点
J Biol Chem. 2002 May 10;277(19):16639-47. doi: 10.1074/jbc.M200360200. Epub 2002 Feb 28.
Zotero 插件